{
    "nct_id": "NCT05388773",
    "official_title": "Phase II Trial of Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer",
    "inclusion_criteria": "* ECOG performance status of 0 or 1 or Karnofsky score 80-100.\n* Newly diagnosed, histologically or cytologically confirmed SCC or undifferentiated carcinoma of the oropharynx and resectable oropharyngeal disease.\n* Patients must be deemed eligible for a TOS procedure with no evidence of distant metastasis as determined by imaging studies.\n* Biopsy-proven p16+ oropharynx cancer; the histologic evidence of invasive squamous cell carcinoma may have been obtained from the primary tumor or metastatic lymph node.\n* Carcinoma of the oropharynx associated with HPV as determined by p16 protein expression using immunohistochemistry (IHC) performed by a CLIA approved laboratory.\n* No prior radiation above the clavicles.\n* Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix, melanoma in-situ (if fully resected), and/or non-melanomatous skin cancer.\n* Patients with congestive heart failure > NYHA Class II, CVA/TIA, unstable angina, or myocardial infarction within the last 6 months prior to registration must be evaluated by a cardiologist and/or neurologist.\n* Acceptable renal and hepatic function within 4 weeks prior to registration as predefined.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* No evidence of extensive or \"matted/fixed\" pathologic adenopathy on preoperative imaging.\n* Women must not be pregnant or breast-feeding due to the teratogenicity of chemotherapy.\n* No intercurrent illness likely to interfere with protocol therapy or prevent surgical resection.\n* No uncontrolled diabetes, infection despite antibiotics, or hypertension within 30 days prior to registration.",
    "miscellaneous_criteria": ""
}